Distribution of KRAS G12C Somatic Mutations across Race, Sex, and Cancer Type

Abstract excerpt

To the Editor: Hong et al. (Sept.24 issue) 1 present results of an early-phase clinical trial of sotorasib, which showed promising clinical benefit.Patients had non-small-cell lung cancer (NSCLC; 46%) or colorectal cancer (33%), and White patients constituted 76% of the cohort.As drugs are being developed for the previously "undruggable" KRAS G12C mutation, it is imperative to study the distribution of this...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to DNA Repair Mechanisms
• Share to Genetic factors in colorectal cancer
• Share to Genomics and Rare Diseases